Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the effects of mexiletine treatment for 6 months
on ambulation, myotonia, muscle function and strength, pain, gastrointestinal functioning,
cardiac conduction, and quality of life in myotonic dystrophy type 1 (DM1).